Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment

Alduais, Yaser; Zhang, Haijun; Fan, Fan; Chen, Jing; Chen, Baoan

doi:10.1097/md.0000000000032899

Cited by 70 publications

(37 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Non-Small Cell Lung Cancer (NSCLC) represents the predominant subtype of lung cancer, accounting for approximately 85% of cases, and it is characterized by a poor prognosis, with a 5-year survival rate of only 19% ( Rodríguez-Abreu et al, 2021 ; Mithoowani and Febbraro, 2022 ). Over the past few decades, various treatment modalities, including surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy, have been employed in the clinical management of NSCLC ( Hopstaken et al, 2021 ; Miller and Hanna, 2021 ; Wang et al, 2021 ; Alduais et al, 2023 ). Despite the significant advances achieved for these treatment strategies, the development of therapy resistance in NSCLC remains a considerable challenge ( Brown et al, 2019 ; Patel and Weiss, 2020 ; Muthusamy et al, 2022 ), thus necessitating the exploration of novel therapeutic approaches for NSCLC.…”

Section: Introductionmentioning

confidence: 99%

Induction of ferroptosis by natural products in non-small cell lung cancer: a comprehensive systematic review

Zhang,

Xia,

Wang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Lung cancer is one of the leading causes of cancer-related deaths worldwide that presents a substantial peril to human health. Non-Small Cell Lung Cancer (NSCLC) is a main subtype of lung cancer with heightened metastasis and invasion ability. The predominant treatment approaches currently comprise surgical interventions, chemotherapy regimens, and radiotherapeutic procedures. However, it poses significant clinical challenges due to its tumor heterogeneity and drug resistance, resulting in diminished patient survival rates. Therefore, the development of novel treatment strategies for NSCLC is necessary. Ferroptosis was characterized by iron-dependent lipid peroxidation and the accumulation of lipid reactive oxygen species (ROS), leading to oxidative damage of cells and eventually cell death. An increasing number of studies have found that exploiting the induction of ferroptosis may be a potential therapeutic approach in NSCLC. Recent investigations have underscored the remarkable potential of natural products in the cancer treatment, owing to their potent activity and high safety profiles. Notably, accumulating evidences have shown that targeting ferroptosis through natural compounds as a novel strategy for combating NSCLC holds considerable promise. Nevertheless, the existing literature on comprehensive reviews elucidating the role of natural products inducing the ferroptosis for NSCLC therapy remains relatively sparse. In order to furnish a valuable reference and support for the identification of natural products inducing ferroptosis in anti-NSCLC therapeutics, this article provided a comprehensive review explaining the mechanisms by which natural products selectively target ferroptosis and modulate the pathogenesis of NSCLC.

show abstract

Section: Introductionmentioning

confidence: 99%

Induction of ferroptosis by natural products in non-small cell lung cancer: a comprehensive systematic review

Zhang,

Xia,

Wang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Global cancer statistics from 2020 reveal that lung cancer comprised 11.4 % of all cancer cases and contributed to 18.0 % of cancer-related deaths worldwide [3]. Histologically, lung cancer can be classified into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with treatment options primarily consisting of surgery, radiation therapy, chemotherapy, and targeted drug therapy [4,5]. However, despite of the above comprehensive treatment strategies, the prognosis of pa-Original Article: Endocrine Care Association Between Metabolic Syndrome and the Risk of Lung Cancer: A Meta-Analysis tients with lung cancer remains poor, highlighting the importance of primary prevention.…”

Section: Introductionmentioning

confidence: 99%

Association Between Metabolic Syndrome and the Risk of Lung Cancer: A Meta-Analysis

Zhang,

Liu,

Huang

et al. 2023

Horm Metab Res

View full text Add to dashboard Cite

Previous studies showed conflicting results regarding the association between metabolic syndrome (MetS) and risk of lung cancer. We performed a systemic review and meta-analysis to determine the relationship between MetS and lung cancer incidence and mortality in adults. Longitudinal follow-up studies were identified by search of Medline, Embase, Cochrane Library, and Web of Science. By incorporating potential heterogeneity into the model, a randomized-effects model was selected to pool the results. Fourteen observational studies were included. Pooled results showed that MetS was associated with a higher risk of lung cancer incidence [risk ratio (RR): 1.15, 95% confidence interval (CI): 1.05 to 1.26, p=0.002; I2=89%). Subgroup analysis suggested that the association was not significantly affected by study country, design, sex of the participants, adjustment of smoking, or different study quality scores (p for subgroup difference all>0.05). The association was predominantly contributed by studies with MetS defined by the National Cholesterol Education Program Adult Treatment Panel-III rather than those with MetS defined by the International Diabetes Foundation criteria, and the association seemed to be stronger in studies with follow-up within 6 years than those over 6 years (p for subgroup difference=0.03 and 0.04, respectively). In addition, pooled results also showed that MetS was associated with a higher risk of lung cancer mortality (RR: 1.46, 95% CI: 1.19 to 1.79, p <0.001; I2=0%). In conclusion, in adult population, MetS may be a risk factor of lung cancer incidence and mortality.

show abstract

“…LC patients suffer from various symptoms, including cough, dyspnoea, pain, fatigue and nausea, as well as emotional disease and social concerns, all of which require health support in many occasions. 2 Advanced LC treatment is based on a systemic therapy consisting of a drug combination (platinum-based chemotherapy and immunotherapy (IT)), IT in monotherapy, or targeted drugs in those patients who carry any targeted molecular alteration (EGFR, ALK, ROS1, etc.). These treatments are associated with a moderate level of toxicity, especially in fragile and highly symptomatic patients.…”

Section: Introductionmentioning

confidence: 99%

M-Health in lung cancer: A literature review

Sereno,

Iniesta-Chamorro,

Garrido-Rubiales

et al. 2023

SAGE Open Medicine

View full text Add to dashboard Cite

The internet and digital technology have become an important resource for patients with cancer. Mobile health strategies permit patients and clinicians to interact via different tools to enrich the supplements to routine hospital visits or out-patient attendance. In this work, we have reviewed different mobile health platforms to support lung cancer patients in different areas: pre-surgery; post-surgery and on systemic treatment. We have also reviewed different digital tools used by long-term lung cancer survivors as well as the impact of these tools on the quality of life, and we tried to analyse according to literature the potential efficiency of these platforms in health system administration.

show abstract

Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment

Cited by 70 publications

References 66 publications

Induction of ferroptosis by natural products in non-small cell lung cancer: a comprehensive systematic review

Induction of ferroptosis by natural products in non-small cell lung cancer: a comprehensive systematic review

Association Between Metabolic Syndrome and the Risk of Lung Cancer: A Meta-Analysis

M-Health in lung cancer: A literature review

Contact Info

Product

Resources

About